Spyre Therapeutics (SYRE) Retained Earnings (2015 - 2026)
Spyre Therapeutics (SYRE) reported Retained Earnings of -$767000.0 for Q1 2026, up 99.92% on a YoY basis from -$383644.6 in Q1 2025, and down 188.26% quarter-over-quarter from $869000.0 in Q4 2025.
Spyre Therapeutics (SYRE) Retained Earnings (2015 - 2026) Analysis & Trends
Spyre Therapeutics has reported Retained Earnings for 12 years, with the latest figure at -$767000.0 in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings rose 99.92% year-over-year to -$767000.0; the trailing twelve-month figure through Mar 2026 stood at -$767000.0 (up 99.92% YoY), and the FY2025 full-year result was $869000.0, up 100.09% from the prior year.
- Retained Earnings for Q1 2026 stood at -$767000.0, down from $869000.0 in the prior quarter.
- The five-year high for Retained Earnings was $869000.0 in Q4 2025, with the low at -$1.1 billion in Q2 2025.
- Historically, Retained Earnings has averaged -$504.8 million across 5 years, with a median of -$444.0 million in 2023.
- Annual changes were most pronounced in 2023 — Retained Earnings surged 729.17% — and 2024, when it sank 322097.35%.
- Spyre Therapeutics' Retained Earnings stood at -$48000.0 in 2022, then jumped by 729.17% to $302000.0 in 2023, then slumped by 322097.35% to -$972.4 million in 2024, then soared by 100.09% to $869000.0 in 2025, then tumbled by 188.26% to -$767000.0 in 2026.
- The last three Retained Earnings figures came in at -$767000.0 (Q1 2026), $869000.0 (Q4 2025), and $791000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | -153.89 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -211.85 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 1.00 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 130.89 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -279.00 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.88 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 14.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -838.07 Mn |
| 10 | Spyre Therapeutics | 6.95 Bn | 6.95 Bn | - | -767,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -767,000.00 |
| Dec 31, 2025 | 869,000.00 |
| Sep 30, 2025 | 791,000.00 |
| Jun 30, 2025 | -1.05 Bn |
| Mar 31, 2025 | -1.02 Bn |
| Dec 31, 2024 | -972.43 Mn |
| Sep 30, 2024 | -916.14 Mn |
| Jun 30, 2024 | -847.10 Mn |
| Mar 31, 2024 | -808.27 Mn |
| Dec 31, 2023 | 302,000.00 |
| Sep 30, 2023 | -701.23 Mn |
| Jun 30, 2023 | -661.13 Mn |
| Mar 31, 2023 | -444.00 Mn |
| Dec 31, 2022 | -48,000.00 |
| Sep 30, 2022 | -406.80 Mn |
| Jun 30, 2022 | -388.57 Mn |
| Mar 31, 2022 | -366.25 Mn |
| Dec 31, 2021 | -341.81 Mn |
| Sep 30, 2021 | -321.40 Mn |
| Jun 30, 2021 | -301.06 Mn |